학술논문
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Document Type
Academic Journal
Author
Zelenetz AD; Memorial Sloan Kettering Cancer Center.; Gordon LI; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.; Abramson JS; Massachusetts General Hospital Cancer Center.; Advani RH; Stanford Cancer Institute.; Andreadis B; UCSF Helen Diller Family Comprehensive Cancer Center.; Bartlett NL; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.; Budde LE; City of Hope National Medical Center.; Caimi PF; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.; Chang JE; University of Wisconsin Carbone Cancer Center.; Christian B; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.; DeVos S; UCLA Jonsson Comprehensive Cancer Center.; Dholaria B; Vanderbilt-Ingram Cancer Center.; Fayad LE; The University of Texas MD Anderson Cancer Center.; Habermann TM; Mayo Clinic Comprehensive Cancer Center.; Hamid MS; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.; Hernandez-Ilizaliturri F; Roswell Park Comprehensive Cancer Center.; Hu B; Huntsman Cancer Institute at the University of Utah.; Kaminski MS; University of Michigan Rogel Cancer Center.; Karimi Y; University of Michigan Rogel Cancer Center.; Kelsey CR; Duke Cancer Institute.; King R; Mayo Clinic Comprehensive Cancer Center.; Krivacic S; Consultant.; LaCasce AS; Dana-Farber/Brigham and Women's Cancer Center.; Lim M; Memorial Sloan Kettering Cancer Center.; Messmer M; Fox Chase Cancer Center.; Narkhede M; O'Neal Comprehensive Cancer Center at UAB.; Rabinovitch R; University of Colorado Cancer Center.; Ramakrishnan P; UT Southwestern Simmons Comprehensive Cancer Center.; Reid E; UC San Diego Moores Cancer Center.; Roberts KB; Yale Cancer Center/Smilow Cancer Hospital.; Saeed H; Moffitt Cancer Center.; Smith SD; Fred Hutchinson Cancer Center.; Svoboda J; Abramson Cancer Center at the University of Pennsylvania.; Swinnen LJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.; Tuscano J; UC Davis Comprehensive Cancer Center.; Vose JM; Fred & Pamela Buffett Cancer Center.; Dwyer MA; National Comprehensive Cancer Network.; Sundar H; National Comprehensive Cancer Network.
Source
Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Print Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE
Subject
Language
English
Abstract
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.